However, subsequent studies identified that YAP1 is probably not the key transcription factor that precisely explains the SCLC subtype, and further discovered and defined SCLC-inflamed or SCLC-I subtype rich in immune and inflammatory phenotypes, where SCLC-I subtype in the latest SCLC subtype was inflammatory and sensitive to immunotherapy, while other subtypes were not (29). The gene discussed is YAP1; the disease is small cell lung carcinoma.